{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042017","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.725742+00:00","generated_at":"2026-05-22T00:09:30.328354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track","bullets":["Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.","Cash and equivalents totaled $48.8M as of March 31, 2025.","BEACON CSU study data (including OLE) expected first half of Q3 2025; Phase 2b planned for H2 2025.","SPOTLIGHT CIndU study full cohort enrolled; additional data at EAACI June 2025.","ETESIAN asthma allergen challenge study enrolling; initial data expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042017","json":"https://secwatch.observer/filing/0001213900-25-042017.json","markdown":"https://secwatch.observer/filing/0001213900-25-042017.md","text":"https://secwatch.observer/filing/0001213900-25-042017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/0001213900-25-042017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025042017/ea0241732-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:09:30.328354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}